Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity an Italian experience

Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity : an Italian experience

Copyright © 2022 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 242(2022) vom: 01. Sept., Seite 109091
1. Verfasser: Infantino, Maria (VerfasserIn)
Weitere Verfasser: Morena, Lorenza, Di Pietro, Massimo Antonio, Romanin, Benedetta, Cimolato, Barbara, Rocca, Beatrice Anna Luisa, Tunnera, Silvia, Modi, Giulia, Tilli, Marta, Grossi, Valentina, Lari, Barbara, Cerutti, Helena, Tesi, Giulia, Anrò, Valentina, Cartocci, Alessandra, Benucci, Maurizio, Veneziani, Francesca, Casprini, Patrizia, Manfredi, Mariangela
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article COVID-19 Inflammatory markers Respiratory support Risk assessment suPAR Biomarkers Interleukin-6 Leukocyte L1 Antigen Complex Receptors, Urokinase Plasminogen Activator Tumor Necrosis Factor-alpha
LEADER 01000naa a22002652 4500
001 NLM344642755
003 DE-627
005 20231226023240.0
007 cr uuu---uuuuu
008 231226s2022 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2022.109091  |2 doi 
028 5 2 |a pubmed24n1148.xml 
035 |a (DE-627)NLM344642755 
035 |a (NLM)35944880 
035 |a (PII)S1521-6616(22)00172-3 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Infantino, Maria  |e verfasserin  |4 aut 
245 1 0 |a Soluble urokinase Plasminogen Activator Receptor (suPAR) levels are predictive of COVID-19 severity  |b an Italian experience 
264 1 |c 2022 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 13.09.2022 
500 |a Date Revised 21.12.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2022 Elsevier Inc. All rights reserved. 
520 |a BACKGROUND: The soluble urokinase Plasminogen Activator Receptor (suPAR) has been identified as a reliable marker of COVID-19 severity, helping in personalizing COVID-19 therapy. This study aims to evaluate the correlation between suPAR levels and COVID-19 severity, in relation to the traditional inflammatory markers 
520 |a METHODS: Sera from 71 COVID-19 patients were tested for suPAR levels using Chorus suPAR assay (Diesse Diagnostica Senese SpA, Italy). suPAR levels were compared with other inflammatory markers: IL-1β, IL-6, TNF-α, circulating calprotectin, neutrophil and lymphocyte counts, and Neutrophil/Lymphocytes Ratio (NLR). Respiratory failure, expressed as P/F ratio, and mortality rate were used as indicators of disease severity 
520 |a RESULTS: A positive correlation of suPAR levels with IL-6 (r = 0.479, p = 0.000), TNF-α (r = 0.348, p = 0.003), circulating calprotectin (r = 0.369, p = 0.002), neutrophil counts (r = 0.447, p = 0.001), NLR (r = 0.492, p = 0.001) has been shown. Stratifying COVID-19 population by suPAR concentration above and below 6 ng/mL, we observed higher levels of circulating calprotectin (10.1 μg/mL, SD 7.9 versus 6.4 μg/mL, SD 7.5, p < 0.001), higher levels of P/F ratio (207.5 IQR 188.3 vs 312.0 IQR 127.8, p = 0.013) and higher mortality rate. Median levels of suPAR were increased in all COVID-19 patients requiring additional respiratory support (Nasal Cannula, Venturi Mask, BPAP and CPAP) (6.5 IQR = 4.9) compared to the group at room air (4.6 IQR = 4.2) 
520 |a CONCLUSION: suPAR levels correlate with disease severity and survival rate of COVID-19 patients, representing a promising prognostic biomarker for the risk assessment of the disease 
650 4 |a Journal Article 
650 4 |a COVID-19 
650 4 |a Inflammatory markers 
650 4 |a Respiratory support 
650 4 |a Risk assessment 
650 4 |a suPAR 
650 7 |a Biomarkers  |2 NLM 
650 7 |a Interleukin-6  |2 NLM 
650 7 |a Leukocyte L1 Antigen Complex  |2 NLM 
650 7 |a Receptors, Urokinase Plasminogen Activator  |2 NLM 
650 7 |a Tumor Necrosis Factor-alpha  |2 NLM 
700 1 |a Morena, Lorenza  |e verfasserin  |4 aut 
700 1 |a Di Pietro, Massimo Antonio  |e verfasserin  |4 aut 
700 1 |a Romanin, Benedetta  |e verfasserin  |4 aut 
700 1 |a Cimolato, Barbara  |e verfasserin  |4 aut 
700 1 |a Rocca, Beatrice Anna Luisa  |e verfasserin  |4 aut 
700 1 |a Tunnera, Silvia  |e verfasserin  |4 aut 
700 1 |a Modi, Giulia  |e verfasserin  |4 aut 
700 1 |a Tilli, Marta  |e verfasserin  |4 aut 
700 1 |a Grossi, Valentina  |e verfasserin  |4 aut 
700 1 |a Lari, Barbara  |e verfasserin  |4 aut 
700 1 |a Cerutti, Helena  |e verfasserin  |4 aut 
700 1 |a Tesi, Giulia  |e verfasserin  |4 aut 
700 1 |a Anrò, Valentina  |e verfasserin  |4 aut 
700 1 |a Cartocci, Alessandra  |e verfasserin  |4 aut 
700 1 |a Benucci, Maurizio  |e verfasserin  |4 aut 
700 1 |a Veneziani, Francesca  |e verfasserin  |4 aut 
700 1 |a Casprini, Patrizia  |e verfasserin  |4 aut 
700 1 |a Manfredi, Mariangela  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 242(2022) vom: 01. Sept., Seite 109091  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:242  |g year:2022  |g day:01  |g month:09  |g pages:109091 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2022.109091  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 242  |j 2022  |b 01  |c 09  |h 109091